Back to Search Results
Study Complete
Sponsor ID
20120310

Historical Data Analysis of Hematological Remission and Survival in Adults with R/R Acute Lymphoblastic Leukemia

Sponsor ID
20120310
Clinicaltrials.gov ID
NCT02003612
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

A retrospective analysis of historical data looking at hematological remission and survival in adult relapsed / refractory B-precursor acute lymphoblastic leukemia patients.

Additional Study Details

Phase
N/A
Product
blinatumomab
Type
Observational
Masking
N/A
Enrollment
2373
Additional Study Details

Protocol Summary

Primary Outcome Measures

hematological complete remission

Timeframe: Approx 1 year

Secondary Outcome Measures

overall survival

Timeframe: Approx 1 year

duration of complete remission

Timeframe: Approx 1 year

proportion of patients receiving allogeneic hematological stem cell transplantation

Timeframe: Approx 1 year

Locations

Location
Status
Contact Us
Location
Research Site
Badalona, Cataluña, Spain, 08916
Status
Recruiting
Location
Research Site
Bologna, Italy, 40138
Status
Recruiting
Location
Research Site
Brno, Czech Republic, 625 00
Status
Recruiting
Location
Research Site
Gliwice, Poland, 44-101
Status
Recruiting
Location
Research Site
London, United Kingdom, NW3 2PF
Status
Recruiting
Location
Research Site
Frankfurt am Main, Germany, 60590
Status
Recruiting
Showing {first} - {last} of {total} Results
Study Info
Age
15+ years
Condition
  • Leukemia
    • Sex
    All
    Trial Dates
    Oct 2013 - Jan 2014
    Inclusion and Exclusion Criteria
    Inclusion Criteria: - adult patients with relapsed / refractory B-precursor acute lymphoblastic leukemia - age 15 or older at time of de novo (initial) diagnosis of acute lymphoblastic leukemia - initial diagnosis of acute lymphoblastic leukemia in the year 1990 or later - No CNS involvement at relapse - No isolated extramedullary relapse - Other inclusion criteria may apply